SpectaCell's $6.5M Bet: Faster Cell Analysis for Cancer Cures

Jan de Vries · 2026-10-09

SpectaCell, a fresh face in the biotech scene from Ghent, Belgium, just launched with $6.5 million in seed funding. That's €6 million converted to USD. The company spun out of imec, VIB, and Ghent University, and it's on a mission to change how we analyze cells for immunotherapy. ### Why Cell Analysis Matters for Immunotherapy Immunotherapies are revolutionizing cancer treatment. They harness the immune system to fight diseases. But there's a catch: predicting which therapies will work in patients is tough. And producing them consistently? Even tougher. Developers often fly blind, waiting days for test results. That delay can cost lives. SpectaCell's platform promises to cut through the fog. It measures how treatments affect individual cells, not just averages. Because let's face it, averages hide important differences. A cancer cell might respond to a therapy while its neighbor doesn't. SpectaCell captures that nuance. > "Breakthrough medicines need breakthrough tools," says Tony Montoye, CEO and co-founder. "Researchers need to know much earlier which candidates deserve further investment and why." ### How SpectaCell's Tech Works At its core, SpectaCell combines chip-based imaging with data analysis. It tracks thousands of individual cells over time, at high resolution. No fluorescent labels needed, which can mess with cell behavior. The result? A clear picture of what a treatment actually does. The company is building a cartridge-based instrument that delivers insights in hours, not days. Think of it like a high-speed camera for cellular interactions. It's designed to be easy to use, fitting into existing workflows from research to manufacturing. ### Who Benefits? SpectaCell targets pharma and biotech companies worldwide. Its platform serves multiple stages: - **Researchers** can compare drug candidates more accurately. - **Development teams** can optimize production processes. - **Manufacturers** can check if each batch meets quality standards. Applications include cell therapies and T-cell engagers, which help immune cells recognize and attack cancer. The potential is huge. ### The Funding and Backers The round was led by imec.xpand, with participation from PMV's Flanders Future Tech Fund, InnovationQuarter Capital, Qbic, and VIB. Benoit Devogelaere, Partner at imec.xpand, sees big things ahead: "SpectaCell brings together disruptive semiconductor technology, an experienced team, and a major commercial opportunity." Founded in 2026 by Mathieu Rabaey, Veronique De Vroey, Jan Van de Velde, and Tony Montoye, SpectaCell is poised to make waves. The capital will fuel further development and commercialization with pharma partners. ### What's Next? The company plans to roll out its platform globally. If successful, it could become the gold standard for cell analysis, speeding up drug development and getting better treatments to patients sooner. And that's something we all can cheer for.